Our study extends the knowledge regarding genes crucial for tumor progression in 17q21-ter gain neuroblastoma patients, and indicates that the ALYREF-USP3-MYCN regulatory complex is valuable as a potential target for the treatment of neuroblastoma by exploiting the enforced ALYREF addiction present in MYCN-amplified cells. The gene discussed is MYCN; the disease is neuroblastoma.